A Partially-Blind, Randomised, Multi-centre Trial to Compare the Anti-Tumour Effects, Pharmacokinetics and Tolerability of 50 mg, 125 mg and 250 mg Single Doses of FASLODEX (Long-Acting ICI 182,780) with Tamoxifen and with Tamoxifen Placebo in Postmenopausal Women Prior to Surgery for Primary Breast Cancer
Study identifier:9238IL/0018
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Partially-Blind, Randomised, Multi-centre Trial to Compare the Anti-Tumour Effects, Pharmacokinetics and Tolerability of 50 mg, 125 mg and 250 mg Single Doses of FASLODEX (Long-Acting ICI 182,780) with Tamoxifen and with Tamoxifen Placebo in Postmenopausal Women Prior to Surgery for Primary Breast Cancer
Medical condition
Breast Cancer
Phase
N/A
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
